Results 151 to 160 of about 77,552 (290)

Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 435-447, March 2025.
Abstract Intranasal diamorphine (IND), approved for managing breakthrough pain in the UK, has been identified as an acceptable alternative offering effective, expedient, and less traumatic analgesia for children. However, the current dose regimen in pediatric populations relies on clinical expertise while the pharmacokinetics properties are poorly ...
Lianjin Cai   +6 more
wiley   +1 more source

Standardized LM Tests for Spatial Error Dependence in Linear or Panel Regressions [PDF]

open access: yes
The robustness of the LM tests for spatial error dependence of Burridge (1980) for the linear regression model and Anselin (1988) for the panel regression model are examined.
Badi H. Baltagi, Zhenlin Yang
core  

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre   +5 more
wiley   +1 more source

Robustness [PDF]

open access: yes
The standard theory of decision making under uncertainty advises the decision maker to form a statistical model linking outcomes to decisions and then to choose the optimal distribution of outcomes.
Lars Peter Hansen, Thomas J. Sargent
core  

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani   +5 more
wiley   +1 more source

Model misspecification, learning and the exchange rate disconnect puzzle [PDF]

open access: yes
Rational expectations models fail to explain the disconnect between the exchange rate and macroeconomic fundamentals. In line with survey evidence on the behaviour of foreign exchange traders, we introduce model misspecification and learning into a ...
Agnieszka Markiewicz, Vivien Lewis
core  

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai   +10 more
wiley   +1 more source

On the fit and forecasting performance of New-Keynesian models [PDF]

open access: yes
The paper provides new tools for the evaluation of DSGE models, and applies it to a large-scale New Keynesian dynamic stochastic general equilibrium (DSGE) model with price and wage stickiness and capital accumulation.
Del Negro, Marco   +3 more
core  

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 540-550, March 2025.
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy